3-氯-5-(三氟甲基)苯硼酸 | 1160561-31-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-5-(三氟甲基)苯硼酸
• 中文别名: 3-氯-5-三氟甲基苯硼酸
• 英文名称: [3-chloro-5-(trifluoromethyl)phenyl]boronic acid
• 英文别名: 3-Chloro-5-(trifluoromethyl)phenylboronic acid
• CAS: 1160561-31-8
• 化学式: C₇H₅BClF₃O₂
• 分子量: 224.375
• InChiKey: VRZOZHNVFRLIPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.04
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 安全说明：
  S36/37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Chloro-5-(trifluoromethyl)phenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-5-(trifluoromethyl)phenylboronic acid
CAS number: 1160561-31-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BClF3O2
Molecular weight: 224.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3-氯-5-三氟甲基苯硼酸主要用于有机和医药中间体。

反应信息

• 作为反应物：
  描述：

  3-氯-5-(三氟甲基)苯硼酸 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 C₁₉H₁₅Cl₂F₃N₄
  参考文献：
  名称：

  Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents

  摘要：

  DOI：

  10.1016/j.bmc.2022.116962
• 作为产物：
  描述：

  间氯三氟甲苯 在 [Ir(COD)(OMe)]2 sodium periodate 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 20.25h， 生成 3-氯-5-(三氟甲基)苯硼酸
  参考文献：
  名称：

  One-Pot Synthesis of Arylboronic Acids and Aryl Trifluoroborates by Ir-Catalyzed Borylation of Arenes

  摘要：

  The synthesis of arylboronic acids and aryl trifluoroborates in a one-pot sequence by Ir-catalyzed borylation of arenes is reported. To prepare the arylboronic acids, the Ir-catalyzed borylation is followed by oxidative cleavage of the boronic ester with NaIO4. To prepare the aryltrifluoroborate, the Ir-catalyzed borylation is followed by displacement of pinacol by KHF2. These two-step sequences give products that are more reactive toward subsequent chemistry than the initially formed pinacol boronates.

  DOI：

  10.1021/ol062903o

文献信息

• 激酶抑制剂
  申请人：曼彻斯特大学

  公开号：CN112119077A

  公开（公告）日：2020-12-22

  本发明涉及某些4‑(取代的苯胺)‑2‑(取代的哌啶‑1‑基)嘧啶‑5‑甲酰胺化合物，其可用于治疗或预防通过CaMK1同种型的信号传导介导的疾病或医学病况。例如，此类化合物及其盐可用于治疗或预防多种不同的癌症、代谢性疾病(包括2型糖尿病)和/或免疫介导的疾病。
• 6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H
  作者：Lei Wang、Jing Tang、Andrew D. Huber、Mary C. Casey、Karen A. Kirby、Daniel J. Wilson、Jayakanth Kankanala、Michael A. Parniak、Stefan G. Sarafianos、Zhengqiang Wang

  DOI：10.1016/j.ejmech.2018.07.035

  日期：2018.8

  Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RNase H) remains an unvalidated drug target. Reported HIV RNase H inhibitors generally lack significant antiviral activity. We report herein the design, synthesis, biochemical and antiviral evaluations of a new 6-biphenylmethyl subtype of the 3-hydroxypyrimidine-2,4-dione (HPD) chemotype. In biochemical assays

  人类免疫缺陷病毒（HIV）逆转录酶（RT）相关的核糖核酸酶H（RNase H）仍然是未经验证的药物靶标。据报道，HIV RNase H抑制剂通常缺乏显着的抗病毒活性。我们在此报告了3-羟基嘧啶-2,4-二酮（HPD）化学型的新的6-联苯甲基亚型的设计，合成，生化和抗病毒评估。在生化分析中，这种新亚型的类似物可在低纳摩尔范围内有效抑制RT RNase H，而在测试的最高浓度下却不会抑制RT聚合酶（pol）或整合酶链转移（INST）。在基于细胞的测定中，一些类似物在低微摩尔范围内抑制HIV，浓度高达100μM，却没有细胞毒性。
• Synthesis and Antitumor Activity of 1-Substituted 1,2,3-Triazole-Mollugin Derivatives
  作者：Han Luo、Yong-Feng Lv、Hong Zhang、Jiang-Miao Hu、Hong-Mei Li、Shou-Jin Liu

  DOI：10.3390/molecules26113249

  日期：——

  A new series of mollugin-1,2,3-triazole derivatives were synthesized using a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction of corresponding O-propargylated mollugin with aryl azides. All the compounds were evaluated for their cytotoxicity on five human cancer cell lines (HL-60, A549, SMMC-7721, SW480, and MCF-7) using MTS assays. Among the synthesized series, most of them showed cytotoxicity

  采用铜(I)催化相应O-炔丙基化莫鲁金与芳基叠氮化物的Huisgen 1,3-偶极环加成反应合成了一系列新的莫鲁金-1,2,3-三唑衍生物。使用 MTS 测定评估所有化合物对五种人类癌细胞系（HL-60、A549、SMMC-7721、SW480 和 MCF-7）的细胞毒性。在合成的系列中，大多数都表现出细胞毒性，最重要的是，化合物14和17对所有五种癌细胞系都表现出显着的细胞毒性。
• Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma
  作者：Xiaopeng Peng、Ling Li、Jingxuan Chen、Yichang Ren、Jin Liu、Ziwen Yu、Hao Cao、Jianjun Chen

  DOI：10.1021/acs.jmedchem.1c01863

  日期：2022.2.10

  A series of 2-phenylthiazole analogues were designed and synthesized as potential histone deacetylase 6 (HDAC6) inhibitors based on compound 12c (an HDAC6/tubulin dual inhibitor discovered by us recently) and CAY10603 (a known HDAC6 inhibitor). Among them, compound XP5 was the most potent HDAC6 inhibitor with an IC50 of 31 nM and excellent HDAC6 selectivity (SI = 338 for HDAC6 over HDAC3). XP5 also

  基于化合物 12c（我们最近发现的 HDAC6/微管蛋白双重抑制剂）和 CAY10603（一种已知的 HDAC6 抑制剂），设计并合成了一系列 2-苯基噻唑类似物，作为潜在的组蛋白脱乙酰酶 6 （HDAC6） 抑制剂。其中，化合物 XP5 是最有效的 HDAC6 抑制剂，IC50 为 31 nM，具有出色的 HDAC6 选择性 （HDAC6 优于 HDAC3 的 SI = 338）。XP5 还显示出对各种癌细胞系的高抗增殖活性，包括 HDACi 耐药的 YCC3/7 胃癌细胞 （IC50 = 0.16–2.31 μM），优于 CAY10603。此外，XP5 （50 mg/kg） 在黑色素瘤肿瘤模型中表现出显着的抗肿瘤功效，肿瘤生长抑制 （TGI） 为 63%，无明显毒性。此外，XP5 与小分子 PD-L1 抑制剂联合使用时，可有效增强体内抗肿瘤免疫反应，肿瘤浸润淋巴细胞增加和 PD-L1 表达水平降低。综上所述，上述结果表明
• [EN] BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXENE DERIVATIVE COMPOUNDS AS CETP INHIBITORS<br/>[FR] COMPOSÉS DÉRIVÉS DE CYCLOHEXÈNE BIARYLE-SUBSTITUÉ OU BIARYLE HÉTÉROCYCLIQUE-SUBSTITUÉ EN TANT QU'INHIBITEURS DE CETP
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2014119947A1

  公开（公告）日：2014-08-07

  The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.

  本发明提供了双芳基或杂环双芳基取代的环己烯衍生物化合物，其异构体或药学上可接受的盐。本发明的化合物显示出一种CETP抑制作用，能够增加HDL-胆固醇水平并降低LDL-胆固醇水平。包含这些化合物的药物组合物对于预防或治疗血脂异常或与血脂异常相关的疾病是有用的。